Get started
Author

Roberta Karpathy

Observed institution: Viralytics Limited (Australia)
OpenAlex ID: A5110629529
Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.
2015 · Robert Hans Ingemar Andtbacka, Brendan D. Curti, et al. · Journal of Clinical Oncology · 69
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
CALM study: A phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma.
2013 · Robert Hans Ingemar Andtbacka, Howard Kaufman, et al. · Journal of Clinical Oncology · 12
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
2016 · Andreas Lundqvist, Vincent van Hoef, et al. · Journal for ImmunoTherapy of Cancer · 11
PDF
Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.
2016 · Hardev S. Pandha, Nicola E. Annels, et al. · Journal of Clinical Oncology · 7
Phase I STORM study (KEYNOTE 200): Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients.
2016 · Hardev S. Pandha, Kevin J. Harrington, et al. · Journal of Clinical Oncology · 5
Abstract CT021: Phase Ib study of a novel immunotherapy combination therapy of intralesional coxsackievirus A21 and systemic ipilimumab in patients with advanced melanoma
2016 · Brendan Curti, Jon Richards, et al. · Cancer Research · 3
Works count: 7
Citation count: 124
H-index: 5
I10-index: 4
Year
Topic
Type